Subject: RXMD Attracts More Media Coverage on Their Fight Against Opioid Abuse

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
RXMD Attracts More Media Coverage on Their Fight Against Opioid Abuse
Hot Stock to WatchHot Stock to Watch

Company: Progressive Care Inc. (OTCQB: RXMD)


Price: 0.0615

Change (%): + 0.0015 (2.50)

Volume: 625,070
RXMD Chart

Progressive Care Inc. Garners Coverage in International Business Times

MIAMI, April 11, 2019 (GLOBE NEWSWIRE) — Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that it has garnered media coverage in International Business Times in an op-ed written by S. Parikh Mars, CEO of Progressive Care Inc. titled, Opioid Epidemic: 21st Century Thinking Needed to Solve a 21st Century Problem.

“It is a true honor to have the opportunity to write about a subject very close to my heart. Progressive Care is doing everything in our power to address the opioid crisis,” said S. Parikh Mars, CEO of Progressive Care Inc. “Progressive Care aims to provide alternatives to opioids that suit each patient’s needs in hopes to lower our patient’s dependence on opioids and fight the epidemic.”

In the opinion piece titled Opioid Epidemic: 21st Century Thinking Needed To Solve A 21st Century Problem, published April 8, 2019 in International Business Times, Mars discusses that in order to address the opioid epidemic, we must first understand it. Mars says, “ Many states have implemented drastic opioid restrictions, manufacturers and pharmaceutical wholesale vendors have limited supply, pain clinics have shut down and doctors willing to prescribe opioids are fewer and further between. Yet, the problem persists across large swaths of the country and the number of people delivering innovative solutions is dwindling. However, the battle is not lost. The solutions we seek may be right under our noses.”

In the article Mars expressed “we need a new way of thinking about pain to begin with. Currently, pain is evaluated on a 1-10 scale to determine severity and medication is prescribed to address this subjective assessment. However, not all pain is created equally, and no two people feel the same pain the same way.” She concludes that “ To end this crisis, we need to use personalized medicine and a more nuanced view of pain and its treatment. We need to think of pain management in terms of effectiveness and not in terms of strength, choosing non-addictive medicines to address patient-specific pain before resorting to opioid therapies.”

Continue Reading

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks